



## Author index

Volume 126 (1996)

- Alam, R., S. Kataoka, S. Alam, F. Yatsu, Inhibition of vascular smooth muscle cell proliferation by the calcium antagonist clentiazem: role of protein kinase C **126**, 207  
Alam, S., see Alam, R. **126**, 207  
Alavi, M.Z., see Wang, H. **126**, 95  
Albanese, M., see Feussner, G. **126**, 177  
Alessandri, C., see Iuliano, L. **126**, 131  
Allegra, L., see Blasi, F. **126**, 341  
Arveiler, D., see Herrmann, S.-M. **126**, 299  
Arveiler, D., see Malinow, M.R. **126**, 27  
Aston, C.E., see Sanghera, D.K. **126**, 35  
Azzi, A., see Şirikçi, Ö. **126**, 253
- Bach, R.G., see Miller, D.D. **126**, 1  
Bailey, S.R., see Miller, D.D. **126**, 1  
Bard, J.-M., see Herrmann, S.-M. **126**, 299  
Barnes, J.F., see Farish, E. **126**, 77  
Blanc, H., see Herrmann, S.-M. **126**, 299  
Blann, A., J. Morris, C. McCollum, Soluble L-selectin in peripheral arterial disease: relationship with soluble E-selectin and soluble P-selectin **126**, 227  
Blasi, F., M.L. Ranzi, M. Erba, P. Tarsia, R. Racanelli, L. Fagetti, L. Allegra, No evidence for the presence of *Helicobacter pylori* in atherosclerotic plaques in abdominal aortic aneurysm specimens **126**, 341  
Blazek, I., see Leitinger, N. **126**, 305  
Bredie, S.J.H., J.M. Vogelaar, P.N.M. Demacker, A.F.H. Stalenhoef, Apolipoprotein E polymorphism influences lipid phenotypic expression, but not the low density lipoprotein subfraction distribution in familial combined hyperlipidemia **126**, 313  
Brown, A., see Farish, E. **126**, 77  
Brun, L.-D., see Torres, A.L. **126**, 163  
Bryan, N., see Zuckerman, S.H. **126**, 65
- Calder, A., see Farish, E. **126**, 77  
Camastra, C., see Iuliano, L. **126**, 131  
Cambien, F., see Herrmann, S.-M. **126**, 299
- Cambien, F., see Malinow, M.R. **126**, 27  
Cameron, J., see Sherrard, B. **126**, 277  
Camps, J., see Joven, J. **126**, 243  
Carrilho, A.J.F., see Lottenberg, A.M.P. **126**, 265  
Chen, Q., see Stulnig, T.M. **126**, 85  
Colavita, A.R., see Iuliano, L. **126**, 131
- Dart, A., see Sherrard, B. **126**, 277  
de Almeida, E., see Jorge, P.A.R. **126**, 43  
Demacker, P.N.M., see Bredie, S.J.H. **126**, 313  
Derr, J., see Mustad, V. **126**, 117  
Després, J.-P., see Torres, A.L. **126**, 163  
Dubick, M.A., see Killion, S.L. **126**, 289  
Ducimetiere, P., see Malinow, M.R. **126**, 27  
Dzien, A., see Hoppeichler, F. **126**, 333
- Endler, G., see Leitinger, N. **126**, 305  
Erba, M., see Blasi, F. **126**, 341  
Eskelson, C.D., see Killion, S.L. **126**, 289  
Espinel, E., see Joven, J. **126**, 243  
Evans, A.E., see Malinow, M.R. **126**, 27  
Evans, A., see Herrmann, S.-M. **126**, 299
- Fagetti, L., see Blasi, F. **126**, 341  
Farish, E., K. Spowart, J.F. Barnes, C.D. Fletcher, A. Calder, A. Brown, D.M. Hart, Effects of postmenopausal hormone replacement therapy on lipoproteins including lipoprotein(a) and LDL subfractions **126**, 77  
Farrar, M., see Miller, D.D. **126**, 1  
Feres, M.C., see Maranhão, R.C. **126**, 15  
Ferrell, R.E., see Sanghera, D.K. **126**, 35  
Feussner, G., M. Albanese, A. Valencia, Three-dimensional structure of the LDL receptor-binding domain of the human apolipoprotein E2 ( $\text{Arg}_{136} \rightarrow \text{Cys}$ ) variant **126**, 177  
Fiorani, P., see Iuliano, L. **126**, 131  
Fletcher, C.D., see Farish, E. **126**, 77  
Folsom, A.R., see Iso, H. **126**, 233  
Frants, R.R., see Sijbrands, E.J.G. **126**, 197

- Gagné, C., see Torres, A.L. 126, 163  
 Gevers Leuven, J.A., see Sijbrands, E.J.G. 126, 197  
 Gianinni, S.D., see Maranhão, R.C. 126, 15  
 Gotto, Jr, A.M., see Yang, C.-Y. 126, 105  
 Gu, Z.-W., see Yang, C.-Y. 126, 105  
 Gylling, H., T.A. Miettinen, Cholesterol absorption and lipoprotein metabolism in type II diabetes mellitus with and without coronary artery disease 126, 325
- Hall, K.A., see Killion, S.L. 126, 289  
 Harada, S., see Iso, H. 126, 233  
 Hart, D.M., see Farish, E. 126, 77  
 Havekes, L.M., see Sijbrands, E.J.G. 126, 197  
 Herrmann, S.-M., H. Blanc, O. Poirier, D. Arveiler, G. Luc, A. Evans, P. Marques-Vidal, J.-M. Bard, F. Cambien, The Gln/Arg polymorphism of human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM Study 126, 299  
 Hintze, T.H., see Stephan, Z.F. 126, 53  
 Hoffer, M.J.V., see Sijbrands, E.J.G. 126, 197  
 Hoppichler, F., M. Lechleitner, C. Traweger, G. Schett, A. Dzien, W. Sturm, Q. Xu, Changes of serum antibodies to heat-shock protein 65 in coronary heart disease and acute myocardial infarction 126, 333  
 Hornstra, G., see van de Vijver, L.P.L. 126, 155  
 Hu, C.-W., see Stephan, Z.F. 126, 53  
 Hunter, G.C., see Killion, S.L. 126, 289
- Iida, M., see Iso, H. 126, 233  
 Iso, H., S. Harada, T. Shimamoto, A.R. Folsom, K. Koike, S. Sato, M. Iida, Y. Komachi, Polymorphism of the apolipoprotein B gene and blood lipid concentrations in Japanese and Caucasian population samples 126, 233  
 Juliano, L., A. Signore, S. Vallabjosula, A.R. Colavita, C. Camastra, G. Ronga, C. Alessandri, E. Sbarigia, P. Fiorani, F. Violi, Preparation and biodistribution of <sup>99m</sup>technetium labelled oxidized LDL in man 126, 131
- Jarosch, E., see Stulnig, T.M. 126, 85  
 Jennings, G., see Sherrard, B. 126, 277  
 Jingami, H., see Matsuoka, N. 126, 221  
 Jorge, P.A.R., M.R. Osaki, E. de Almeida, L.C. Neto, K. Metze, Effects of vitamin E on endothelium-dependent coronary flow in hypercholesterolemic dogs 126, 43  
 Joven, J., E. Espinel, J.M. Simó, E. Vilella, J. Camps, A. Oliver, The influence of hypoalbuminemia in the generation of nephrotic hyperlipidemia 126, 243  
 Jürgens, G., see Stulnig, T.M. 126, 85
- Kambom, M.I., see Sanghera, D.K. 126, 35  
 Kataoka, S., see Alam, R. 126, 207  
 Killion, S.L., G.C. Hunter, C.D. Eskelson, M.A. Dubick, C.W. Putnam, K.A. Hall, C.A. Luedke, R.L. Misiorowski, J.D. Schilling, K.E. McIntyre, Vitamin E levels in human atherosclerotic plaque: the influence of risk factors 126, 289  
 Kimm, S.Y.S., see Sanghera, D.K. 126, 35
- Kobayashi, K., see Taniguchi, S. 126, 143  
 Koike, K., see Iso, H. 126, 233  
 Komachi, Y., see Iso, H. 126, 233  
 Kris-Etherton, P.M., see Mustad, V. 126, 117  
 Kruyssen, D.A.C.M., see van de Vijver, L.P.L. 126, 155
- Lamarche, B., see Torres, A.L. 126, 163  
 Lechleitner, M., see Hoppichler, F. 126, 333  
 Leitinger, N., C. Pirich, I. Blazek, G. Endler, H. Sinzinger, Decreased susceptibility of low-density lipoproteins to in vitro oxidation after dextran-sulfate LDL-apheresis treatment 126, 305  
 Leonards, K.S., see Stephan, Z.F. 126, 53  
 Lottenberg, A.M.P., V.S. Nunes, S.A. Lottenberg, A.F.M. Shimabukuro, A.J.F. Carrilho, S. Malagutti, E.R. Nakandakare, R. McPherson, E.C.R. Quintão, Plasma cholesterol ester synthesis, cholesterol ester transfer protein concentration and activity in hypercholesterolemic women: effects of the degree of saturation of dietary fatty acids in the fasting and postprandial states 126, 265  
 Lottenberg, S.A., see Lottenberg, A.M.P. 126, 265  
 Luc, G., see Herrmann, S.-M. 126, 299  
 Luc, G., see Malinow, M.R. 126, 27  
 Luedke, C.A., see Killion, S.L. 126, 289  
 Lupien, P.-J., see Torres, A.L. 126, 163
- Malagutti, S., see Lottenberg, A.M.P. 126, 265  
 Malinow, M.R., P. Ducimetiere, G. Luc, A.E. Evans, D. Arveiler, F. Cambien, B.M. Upson, Plasma homocyst(e)ine levels and graded risk for myocardial infarction: findings in two populations at contrasting risk for coronary heart disease 126, 27  
 Maranhão, R.C., M.C. Feres, M.T. Martins, C.H. Mesquita, O. Toffoletto, C.G.C. Vinagre, S.D. Gianinni, F. Pileggi, Plasma kinetics of a chylomicron-like emulsion in patients with coronary artery disease. 126, 15  
 Marques-Vidal, P., see Herrmann, S.-M. 126, 299  
 Martins, M.T., see Maranhão, R.C. 126, 15  
 Masuzaki, H., see Matsuoka, N. 126, 221  
 Matsuoka, N., H. Jingami, H. Masuzaki, M. Mizuno, S. Nakaishi, J. Suga, T. Tanaka, T. Yamamoto, K. Nakao, Effects of gemfibrozil administration on very low density lipoprotein receptor mRNA levels in rabbits 126, 221  
 McAllister, A.E., see Sanghera, D.K. 126, 35  
 McCollum, C., see Blann, A. 126, 227  
 McIntyre, K.E., see Killion, S.L. 126, 289  
 McPherson, R., see Lottenberg, A.M.P. 126, 265  
 Meinders, A.E., see Sijbrands, E.J.G. 126, 197  
 Mesquita, C.H., see Maranhão, R.C. 126, 15  
 Metze, K., see Jorge, P.A.R. 126, 43  
 Miettinen, T.A., see Gylling, H. 126, 325  
 Miller, D.D., R.G. Bach, F.O. Tio, S.R. Bailey, C.A. Waters, T.G. Woodworth, J.C. Nichols, S.B. Paige, M. Farrar, Interleukin-2 receptor-specific fusion toxin inhibits barotrauma-induced arterial atherosclerosis 126, 1  
 Misiorowski, R.L., see Killion, S.L. 126, 289  
 Mizuno, M., see Matsuoka, N. 126, 221

- Moll, D., see Stulnig, T.M. **126**, 85  
 Moore, S., see Wang, H. **126**, 95  
 Moorjani, S., see Torres, A.L. **126**, 163  
 Morris, J., see Blann, A. **126**, 227  
 Mourão, P.A.S., see Tovar, A.M.F. **126**, 185  
 Mustad, V., J. Derr, C.C. Reddy, T.A. Pearson, P.M. Kris-Etherton, Seasonal variation in parameters related to coronary heart disease risk in young men **126**, 117
- Nakaishi, S., see Matsuoka, N. **126**, 221  
 Nakandakare, E.R., see Lottenberg, A.M.P. **126**, 265  
 Nakao, K., see Matsuoka, N. **126**, 221  
 Nawata, H., see Taniguchi, S. **126**, 143  
 Neto, L.C., see Jorge, P.A.R. **126**, 43  
 Nichols, J.C., see Miller, D.D. **126**, 1  
 Nunes, V.S., see Lottenberg, A.M.P. **126**, 265
- Oliver, A., see Joven, J. **126**, 243  
 Osaki, M.R., see Jorge, P.A.R. **126**, 43  
 Özer, N.K., see Şirikçi, Ö. **126**, 253
- Paige, S.B., see Miller, D.D. **126**, 1  
 Pearson, T.A., see Mustad, V. **126**, 117  
 Pileggi, F., see Maranhão, R.C. **126**, 15  
 Pirich, C., see Leitinger, N. **126**, 305  
 Poirier, O., see Herrmann, S.-M. **126**, 299  
 Putnam, C.W., see Killion, S.L. **126**, 289
- Quintão, E.C.R., see Lottenberg, A.M.P. **126**, 265  
 Quion, J.A.V., see Yang, C.-Y. **126**, 105
- Raccanelli, R., see Blasi, F. **126**, 341  
 Ranzi, M.L., see Blasi, F. **126**, 341  
 Reddy, C.C., see Mustad, V. **126**, 117  
 Ronga, G., see Iuliano, L. **126**, 131
- Sanghera, D.K., R.E. Ferrell, C.E. Aston, A.E. McAllister, M.I. Kamboh, S.Y.S. Kimm, Quantitative effects of the apolipoprotein E polymorphism in a biracial sample of 9–10-year-old girls **126**, 35  
 Sato, S., see Iso, H. **126**, 233  
 Sbarigia, E., see Iuliano, L. **126**, 131  
 Schett, G., see Hoppichler, F. **126**, 333  
 Schilling, J.D., see Killion, S.L. **126**, 289  
 Schönitzer, D., see Stulnig, T.M. **126**, 85  
 Sharif, R., see Stephan, Z.F. **126**, 53  
 Sherrard, B., H. Simpson, J. Cameron, S. Wahi, G. Jennings, A. Dart, LDL particle size in subjects with previously unsuspected coronary heart disease: relationship with other cardiovascular risk markers **126**, 277  
 Shimabukuro, A.F.M., see Lottenberg, A.M.P. **126**, 265  
 Shimamoto, T., see Iso, H. **126**, 233  
 Signore, A., see Iuliano, L. **126**, 131  
 Sijbrands, E.J.G., R.G.J. Westendorp, M.J.V. Hoffer, R.R. Frants, A.E. Meinders, J.H.M. Souverijn, J.A. Gevers Leuven, A. Van der Laarse, L.M. Havekes, A.H.M. Smelt, Effect of apolipoprotein E and insulin resistance on VLDL particles in combined hyperlipidemic patients **126**, 197  
 Simó, J.M., see Joven, J. **126**, 243  
 Simpson, H., see Sherrard, B. **126**, 277  
 Sinzinger, H., see Leitinger, N. **126**, 305  
 Şirikçi, Ö., N.K. Özer, A. Azzi, Dietary cholesterol-induced changes of protein kinase C and the effect of vitamin E in rabbit aortic smooth muscle cells **126**, 253  
 Smelt, A.H.M., see Sijbrands, E.J.G. **126**, 197  
 Souverijn, J.H.M., see Sijbrands, E.J.G. **126**, 197  
 Spowart, K., see Farish, E. **126**, 77  
 Stalenhoef, A.F.H., see Bredie, S.J.H. **126**, 313  
 Steele, R.E., see Stephan, Z.F. **126**, 53  
 Stephan, Z.F., E.C. Yurachek, R. Sharif, J.M. Wasvary, K.S. Leonards, C.-W. Hu, T.H. Hintze, R.E. Steele, Demonstration of potent lipid-lowering activity by a thiomimetic agent devoid of cardiovascular and thermogenic effects **126**, 53  
 Stulnig, T.M., G. Jürgens, Q. Chen, D. Moll, D. Schönitzer, E. Jarosch, G. Wick, Properties of low density lipoproteins relevant to oxidative modifications change paradoxically during aging **126**, 85  
 Sturm, W., see Hoppichler, F. **126**, 333  
 Suga, J., see Matsuoka, N. **126**, 221
- Takanayagi, R., see Taniguchi, S. **126**, 143  
 Tanaka, T., see Matsuoka, N. **126**, 221  
 Taniguchi, S., T. Yanase, K. Kobayashi, R. Takanayagi, H. Nawata, Dehydroepiandrosterone markedly inhibits the accumulation of cholestryler ester in mouse macrophage J774-1 cells **126**, 143  
 Tarsia, P., see Blasi, F. **126**, 341  
 Tio, F.O., see Miller, D.D. **126**, 1  
 Toffoletto, O., see Maranhão, R.C. **126**, 15  
 Torres, A.L., S. Moorjani, M.-C. Vohl, C. Gagné, B. Lamarche, L.-D. Brun, P.-J. Lupien, J.-P. Després, Heterozygous familial hypercholesterolemia in children: low-density lipoprotein receptor mutational analysis and variation in the expression of plasma lipoprotein-lipid concentrations. **126**, 163  
 Tovar, A.M.F., P.A.S. Mourão, High affinity of a fucosylated chondroitin sulfate for plasma low density lipoprotein **126**, 185  
 Traweger, C., see Hoppichler, F. **126**, 333
- Upson, B.M., see Malinow, M.R. **126**, 27
- Valencia, A., see Feussner, G. **126**, 177  
 Valentínova, N.V., see Yang, C.-Y. **126**, 105  
 Vallabjosula, S., see Iuliano, L. **126**, 131  
 Van der Laarse, A., see Sijbrands, E.J.G. **126**, 197  
 van de Vijver, L.P.L., G. van Poppel, A. van Houwelingen, D.A.C.M. Kruyssen, G. Hornstra, *Trans* unsaturated fatty acids in plasma phospholipids and coronary heart disease: a case-control study **126**, 155  
 van Houwelingen, A., see van de Vijver, L.P.L. **126**, 155

- van Poppel, G., see van de Vijver, L.P.L. 126, 155  
Vilella, E., see Joven, J. 126, 243  
Vinagre, C.G.C., see Maranhão, R.C. 126, 15  
Violi, F., see Iuliano, L. 126, 131  
Vogelaar, J.M., see Bredie, S.J.H. 126, 313  
Vohl, M.-C., see Torres, A.L. 126, 163  
  
Wahl, S., see Sherrard, B. 126, 277  
Wang, H., S. Moore, M.Z. Alavi, Synthesis of tissue inhibitor of metalloproteinase-1 (TIMP-1) in rabbit aortic neointima after selective de-endothelialization 126, 95  
Wasvary, J.M., see Stephan, Z.F. 126, 53  
Waters, C.A., see Miller, D.D. 126, 1  
Westendorp, R.G.J., see Sijbrands, E.J.G. 126, 197  
Wick, G., see Stulnig, T.M. 126, 85  
Woodworth, T.G., see Miller, D.D. 126, 1  
  
Xie, Y.-H., see Yang, C.-Y. 126, 105  
  
Xu, Q., see Hoppichler, F. 126, 333  
  
Yamamoto, T., see Matsuoka, N. 126, 221  
Yanase, T., see Taniguchi, S. 126, 143  
Yang, C.-Y., Z.-W. Gu, Y.-H. Xie, N.V. Valentinova, M. Yang, D. Yeshurun, J.A.V. Quion, A.M. Gotto, Jr, Effects of gemfibrozil on very-low-density lipoprotein composition and low-density lipoprotein size in patients with hypertriglyceridemia or combined hyperlipidemia 126, 105  
Yang, M., see Yang, C.-Y. 126, 105  
Yatsu, F., see Alam, R. 126, 207  
Yeshurun, D., see Yang, C.-Y. 126, 105  
Yurachek, E.C., see Stephan, Z.F. 126, 53  
  
Zuckerman, S.H., N. Bryan, Inhibition of LDL oxidation and myeloperoxidase dependent tyrosyl radical formation by the selective estrogen receptor modulator raloxifene (LY139481 HCL) 126, 65



## Subject index

Volume 126 (1996)

- Abdominal aortic aneurysm 126, 341  
Acetylcholine 126, 43  
African American disease risk 126, 35  
Aging 126, 85  
Angioplasty 126, 1  
Antibodies 126, 333  
Anti-oxidants 126, 85  
Apo B gene 126, 233  
ApoE 126, 197  
Apo E2 ( $\text{Arg}_{136} \rightarrow \text{Cys}$ ) 126, 177  
Apolipoprotein A-I 126, 117  
Apolipoprotein B100 126, 117  
Apolipoprotein E 126, 35, 105, 177  
Apolipoprotein E polymorphism 126, 313  
Atherosclerosis 126, 1, 53, 85, 95, 131, 207, 227, 253, 299, 305, 333  
Atherosclerotic risk factors 126, 289  
  
Blood total cholesterol 126, 233  
  
Calcium antagonist 126, 207  
Children 126, 163  
Cholesterol 126, 15, 53  
Cholesterol absorption and synthesis 126, 325  
Cholesterol esterification 126, 143  
Cholesterol ester reduction 126, 143  
Cholesteryl ester cycle 126, 143  
Cholesteryl ester storage 126, 143  
Cholesteryl ester transfer protein 126, 265  
Chondroitin 6-sulfate 126, 185  
Chylomicrons 126, 15  
Clentiazem 126, 207  
Combined hyperlipidemia 126, 197  
Coronary artery disease 126, 15, 325  
Coronary atherosclerosis 126, 155  
Coronary heart disease 126, 27, 277, 333, 341  
Coronary risk factors 126, 233  
Cross-cultural comparison 126, 233  
Cytokines 126, 1  
Cytotoxic therapy 126, 1  
  
Dehydroepiandrosterone (DHEA) 126, 143  
Dextrane-sulfate LDL-apheresis 126, 305  
DHEA analogue 126, 143  
Dog 126, 43  
Dominant mode of inheritance 126, 177  
Dysbeta lipoproteinemia 126, 177  
  
Emulsions 126, 15  
Endothelium-dependent coronary flow 126, 43  
Extracellular matrix 126, 95  
  
Familial combined hyperlipidemia 126, 313  
Familial hypercholesterolemia 126, 163  
Free radicals 126, 131  
Fucans 126, 185  
Fucosylated chondroitin sulfate 126, 185  
Fusion toxin 126, 1  
  
Gemfibrozil 126, 105, 221  
Gene expression 126, 95  
Genetic epidemiology 126, 163  
Genetic polymorphism 126, 35  
Genetics 126, 313  
Glucose 126, 277  
Glycosaminoglycans 126, 185  
  
Heat shock proteins 126, 333  
*Helicobacter pylori* 126, 341  
Heparin 126, 185  
Hormone replacement 126, 77  
Hypercholesterolemia 126, 43, 265  
Hyperinsulinemia 126, 197  
Hyperlipidemia 126, 105, 243  
Hypertension 126, 207  
Hypoalbuminemia 126, 243  
Hypolipidemic 126, 53  
  
Imaging 126, 131  
Injury 126, 95  
In situ hybridization 126, 95

- Insulin **126**, 277  
 Interleukin-2 **126**, 1  
 Isoprostanes **126**, 305  
 6-keto-PGF<sub>1 $\alpha$</sub>  **126**, 117  
 LDL **126**, 53, 185  
 LDL and HDL kinetics **126**, 325  
 LDL-biodistribution **126**, 131  
 LDL-cholesterol **126**, 35  
 LDL-oxidation **126**, 305  
 LDL-receptor gene **126**, 163  
 LDL size **126**, 105  
 LDL subfractions **126**, 77  
 Lecithin-cholesterol-acyl transferase **126**, 265  
 Lipid peroxidation **126**, 85  
 Lipid peroxides **126**, 289  
 Lipoperoxides **126**, 65  
 Lipoprotein(a) **126**, 77  
 Lipoproteins **126**, 15, 77, 131, 185, 243  
 Low density lipoprotein particle size **126**, 277  
 Low density lipoproteins **126**, 65  
 Low-density lipoproteins (LDL) **126**, 85  
 L-T<sub>3</sub> **126**, 53  
 lysosomal cholesterol transport **126**, 143  
 Macrophages **126**, 65  
 Membranous nephropathy **126**, 243  
 Myocardial infarction **126**, 27, 299, 333  
 Nephrotic syndrome **126**, 243  
 Oncotic pressure **126**, 243  
 Oxidation **126**, 65  
 Oxidized-LDL **126**, 131  
 Paraoxonase **126**, 299  
 Particle size **126**, 197  
 Phagocytosis **126**, 65  
 Phenotypic expression **126**, 313  
 Phospholipids **126**, 155  
 Plant sterols **126**, 325  
 Plasma homocyst(e)ine **126**, 27  
 Plasma lipoproteins **126**, 35, 105  
 Polymorphism **126**, 233, 299  
 Polyunsaturated fatty acids **126**, 85, 265  
 Postmenopausal **126**, 77  
 Proliferation **126**, 207  
 Protein kinase C **126**, 207, 253  
 Proteinuria **126**, 243  
 Rabbit **126**, 221  
 Risk factors **126**, 27  
 RT-PCR **126**, 95  
 Saturated fatty acids **126**, 265  
 Seasonal variation **126**, 117  
 SENIEUR protocol **126**, 85  
 Smooth muscle cells **126**, 207, 253  
 Sodium nitroprusside **126**, 43  
 Soluble E-selectin **126**, 227  
 Soluble L-selectin **126**, 227  
 Soluble P-selectin **126**, 227  
 Sulfated polysaccharides **126**, 185  
 Thiobarbituric acid reactive substances **126**, 305  
 Thymomimetic **126**, 53  
 TIMP **126**, 95  
 Trans fatty acid **126**, 155  
 Triglyceride **126**, 277  
 Triglycerides **126**, 15  
 TXB<sub>2</sub> **126**, 117  
 Type II diabetes mellitus **126**, 325  
 Type III hyperlipoproteinemia **126**, 177  
 Vitamin E **126**, 43, 253, 289  
 VLDL **126**, 197  
 VLDL composition **126**, 105  
 VLDL receptor **126**, 221  
 VLDL subfractions **126**, 105

